Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), A. V. Snegovoy(Moscow State University of Medicine and Dentistry), Christian F. Singer(Comprehensive Cancer Center Vienna), François P. Duhoux(Cliniques Universitaires Saint-Luc), Christian Schem(Krankenhaus Jerusalem), Ida Paris(Agostino Gemelli University Polyclinic), Henrik Lindman(Uppsala University), Antonio Ciaccio(University of Turin), Fabrizio Luppi(University of Modena and Reggio Emilia), Romano Danesi(University of Milan), Kalhil Zaman(Breast Center), Ahmed Samreen(Leicester Royal Infirmary), Dimitrios Mavroudis(University Hospital of Heraklion), Corrado Girmenia(Policlinico Umberto I)
Cited by 10
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k